

10 Aug 2020 |

Quick Listen: Scrip's Five Must-Know Things

Corporate Pandemic Impact, Important US Launches And RSV Overview

by **Ian Haydock**

Join us for a quick audio roundup of five useful things to know from *Scrip's* recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around *Scrip's* Five Must-Know Things, in this episode covering major developments in the business week ended 7 August 2020.

Making headlines this time are the corporate impact of the coronavirus pandemic, new launches for depression and lymphoma in the US and an overview of progress in the RSV space.

Stories mentioned in this episode:

(Also see "[Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales](#)" - Scrip, 31 Jul, 2020.)

(Also see "[Bayer Q2 Pharma Sales Ravaged By COVID-19](#)" - Scrip, 4 Aug, 2020.)

(Also see "[US FDA Opens Door For J&J's Spravato To Another MDD Population](#)" - Scrip, 3 Aug, 2020.)

(Also see "[Morphosys/Incyte's Monjuvi Wins Early US FDA Approval In Second-Line DLBCL](#)" - Scrip, 4 Aug, 2020.)

(Also see "[Progress In Pharma's Slow Battle Against Respiratory Syncytial Virus](#)" - Scrip, 7 Aug, 2020.)

[Click here to explore this interactive content online](#) 